[Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma.
Carroccio
Antonio
A
Istituto di Medicina Interna, Università, Palermo. acarroccio@hotmail.com
Di Prima
Lidia
L
Pirrone
Giuseppe
G
Ambrosiano
Giuseppe
G
Noto
Davide
D
Cefalù
Angelo B
AB